Sonoma inks exclusive US distribution deal with WellSpring for Microcyn products

Sonoma Pharmaceuticals, Inc.

Exclusive US distribution agreement with WellSpring Pharmaceutical, effective Jan 29, 2025.
Initial term of 2 years with three automatic one-year renewal periods.
WellSpring to distribute Microcyn-based products through defined channels; Sonoma retains all IP.
WellSpring must use commercially reasonable efforts and cannot sell competing hypochlorous acid products in those channels.
Pricing, minimum quantities, and forecasts are set in confidential attachments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.